Products with
Anti-inflammatory bioactivity
Cat.No.
|
Product Name
|
BCN1027 |
Crocin II
|
Crocin has antihyperlipidemic, antidepressant , anti-inflammatory and anti-apoptotic effects. It can reduce the protein expression of iNOS and caspase-3, and increase CREB, BDNF and VGF levels in hippocampus. |
BCN1028 |
Morin
|
Morin, a α-glucosidase inhibitor with an IC50 value of (4.48 ± 0.04) uM, it also exhibits inhibition in the generation of advanced glycation end products which was related to the long term complications of diabetes. Morin has anti-inflammatory and anti-oxidative effects by activating Nrf2 signal pathways and inhibiting NF-κB activation. it can be used to prevent bladder cancer, it prevents MMP-9 expression via the inhibition of transcription factors AP-1, Sp-1, and NF-κB. |
BCN1030 |
6-Gingerol
|
6-Gingerol possesses anti-adipogenic, anti-tumorigenic, anti-invasive, antioxidant, anti-inflammatory, and pro-apoptotic activities, it stimulates apoptosis through upregulation of NAG-1 and G1 cell cycle arrest through downregulation of cyclin D1, multiple mechanisms appear to be involved in 6-gingerol action, including protein degradation as well as β-catenin, PKCε, and GSK-3β pathways. 6-Gingerol can effectively suppress adipogenesis and that it exerts its role mainly through the significant down-regulation of PPARγ and C/EBPα and subsequently inhibits FAS and aP2 expression, also inhibit differentiation in 3T3-L1 cells by attenuating the Akt/GSK3β pathway. |
BCN1031 |
Ligustilide
|
Ligustilide possesses neuroprotective, vasorelaxation, antinociceptive and anti-inflammatory activities, it blocked the activation of MAPKs/IKK and the downstream transcription factors AP-1 and NF-κB. It has the potential to be developed into an effective drug for the treatment of various pain syndromes including primary dysmenorrhoea. |
BCN1033 |
Alantolactone
|
Alantolactone, an allergenic sesquiterpene lactone, has significant antitumor effects on malignant tumor cells, it can suppress inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells, and inhibit cell proliferation by interrupting the interaction between Cripto-1 and activin receptor type II A in activin signaling pathway. |